Autolus Therapeutics (AUTL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$117.4M

Revenue (quarter)

$45.7M

Revenue growth (year over year)

+118.37%

Gross profit (trailing twelve months)

$18.4M

Gross margin

15.66%

Net income (trailing twelve months)

−$280.2M

Net income (quarter)

−$39.1M

Net income growth (year over year)

+18.38%

Net margin

−238.65%

Return on equity

−133.00%

EPS (trailing twelve months)

−$1.06

Book value per share

$0.28

P/E (trailing twelve months)

—

Price to book

6.01

Debt to assets

84.83%

Payout ratio

—

Dividend yield

—

Company profile

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

• Is Autolus Therapeutics (AUTL) profitable?

  No. Autolus Therapeutics reported a net loss of $280.2M over the trailing twelve months.

• How much revenue does Autolus Therapeutics (AUTL) make?

  Autolus Therapeutics generated $117.4M in revenue over the trailing twelve months, up 118.37% year over year.

• How do I buy stock in Autolus Therapeutics (AUTL)?

  AUTL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.